36 hasil
Menampilkan 1–20 · 0,93 detik · RSS
Hepatology
Scopus
ISSN 0270-9139 · Lippincott Williams & Wilkins · 36 artikel di indeks
-
Artikel Jurnal
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis
Kaplan, David E.; Bosch, Jaime; Ripoll, Cristina; Thiele, Maja; Fortune, Brett E.; Simonetto, Douglas A.; Garcia-Tsao, Guadalupe Author Information
-
Artikel Jurnal Teks lengkap
Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
This commentary discusses how clinicians and various stakeholders can utilize the recently published American Association for the Study of Liver Diseases nonalcoholic fatty liver disease (AASLD NAFLD) Practice Guidance in light of the change in the nomenclature to steatotic liver disease and its…
-
Artikel Jurnal Teks lengkap
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
PREAMBLE The study of NAFLD has intensified significantly, with more than 1400 publications since 2018, when the last American Association for the Study of Liver Diseases (AASLD) Guidance document was published.1 This new AASLD Guidance document reflects many advances in the field pertinent to any…
-
Artikel Jurnal Teks lengkap
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author…
-
Artikel Jurnal Teks lengkap
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified…
-
Artikel Jurnal Teks lengkap
Endoplasmic reticulum stress in liver diseases
The endoplasmic reticulum (ER) is an intracellular organelle that fosters the correct folding of linear polypeptides and proteins, a process tightly governed by the ER-resident enzymes and chaperones. Failure to shape the proper 3-dimensional architecture of proteins culminates in the accumulation…
-
Artikel Jurnal Teks lengkap
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
INTRODUCTION There are currently more than 1000 prescription medications available for use in the United States and more than 100,000 over‐the‐counter herbal and dietary supplements (HDS) available for purchase in retail stores and online. In addition, the average adult American receives more than…
-
Artikel Jurnal Teks lengkap
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer-related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the…
-
Artikel Jurnal
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD
Abstract Background and Aims NAFLD and its more‐advanced form, steatohepatitis (NASH), is associated with obesity and is an independent risk factor for cardiovascular, liver‐related, and all‐cause mortality. Available human data examining hepatic mitochondrial fatty acid oxidation (FAO) and hepatic…
-
Artikel Jurnal
NAFLD‐related hepatocellular carcinoma: The growing challenge
Hepatocellular carcinoma (HCC) is a common cause of cancer-related mortality and morbidity worldwide. With the obesity pandemic, NAFLD-related HCC is contributing to the burden of disease exponentially. Genetic predisposition and clinical risk factors for NAFLD-related HCC have been identified…
-
Artikel Jurnal Teks lengkap
Health disparities in chronic liver disease
The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations…
-
Artikel Jurnal
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
BACKGROUND AND AIMS: Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function. APPROACH AND RESULTS: In 216 patients with HCC who were…
-
Artikel Jurnal
Emerging immunotherapy for HCC: A guide for hepatologists
HCC is one of the most common cancers worldwide, and the third leading cause of cancer-related death globally. HCC comprises nearly 90% of all cases of primary liver cancer. Approximately half of all patients with HCC receive systemic therapy during their disease course, particularly in the…
-
Artikel Jurnal
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
This is a comprehensive guidance on the diagnosis, evaluation, and management of ascites and hepatorenal syndrome (HRS) in patients with chronic liver disease from the American Association for the Study of Liver Diseases (AASLD). It replaces the prior AASLD guideline on the same topic published in…
-
Artikel Jurnal Teks lengkap
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major…
-
Artikel Jurnal Teks lengkap
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in…
-
Artikel Jurnal
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Steady progress over four decades toward understanding the pathogenesis and clinical consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet none has been approved. Thus, an assessment of the field is timely, to clarify priorities and accelerate progress…
-
Artikel Jurnal Teks lengkap
Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study
Abstract Background and Aims The risk factors of cholelithiasis have not been clearly identified, especially for total cholesterol. Here, we try to identify these causal risk factors. Approach and Results We obtained genetic variants associated with the exposures at the genome‐wide significance (p…
-
Artikel Jurnal Teks lengkap
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
Supported by the American Association for the Study of Liver Diseases. Dr. Lai is partially supported by R01 AG059183 and R21 AG067554. Srinivasan Dasarathy is partially supported by NIH RO1 GM119174; RO1 DK113196; P50 AA024333; RO1 AA021890; 3U01AA026976 ‐ 03S1; UO1 AA 026976; R56HL141744;UO1…
-
Artikel Jurnal
Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
BACKGROUND AND AIMS: Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unresectable HCC. The aim of the LEGACY (Local radioEmbolization using Glass Microspheres for the Assessment of Tumor Control with Y-90) study was to evaluate objective…